TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05649683

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Evaluation of cytokine production
Description: The patient will have samples at initiation of treatment (J0), after treatments 1 and 2 (S6), after the first radiological assessment at S11 and/or the progression of the disease and/or occurrence of a grade 3-4 adverse event
Study: NCT04813354

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ELLIPTA
Description: * ELLIPTA followed by BREEZHALER/ Preference Questionnaire version 1~* ELLIPTA followed by BREEZHALER/ Preference Questionnaire version 2~* BREEZHALER followed by ELLIPTA/ Preference Questionnaire version 1~* BREEZHALER followed by ELLIPTA/ Preference Questionnaire version 2

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ELLIPTA
Description: * ELLIPTA followed by BREEZHALER/ Preference Questionnaire version 1~* ELLIPTA followed by BREEZHALER/ Preference Questionnaire version 2~* BREEZHALER followed by ELLIPTA/ Preference Questionnaire version 1~* BREEZHALER followed by ELLIPTA/ Preference Questionnaire version 2

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ELLIPTA
Description: * ELLIPTA followed by BREEZHALER/ Preference Questionnaire version 1~* ELLIPTA followed by BREEZHALER/ Preference Questionnaire version 2~* BREEZHALER followed by ELLIPTA/ Preference Questionnaire version 1~* BREEZHALER followed by ELLIPTA/ Preference Questionnaire version 2

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ELLIPTA
Description: * ELLIPTA followed by BREEZHALER/ Preference Questionnaire version 1~* ELLIPTA followed by BREEZHALER/ Preference Questionnaire version 2~* BREEZHALER followed by ELLIPTA/ Preference Questionnaire version 1~* BREEZHALER followed by ELLIPTA/ Preference Questionnaire version 2

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BREEZHALER
Description: * ELLIPTA followed by BREEZHALER/ Preference Questionnaire version 1~* ELLIPTA followed by BREEZHALER/ Preference Questionnaire version 2~* BREEZHALER followed by ELLIPTA/ Preference Questionnaire version 1~* BREEZHALER followed by ELLIPTA/ Preference Questionnaire version 2

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BREEZHALER
Description: * ELLIPTA followed by BREEZHALER/ Preference Questionnaire version 1~* ELLIPTA followed by BREEZHALER/ Preference Questionnaire version 2~* BREEZHALER followed by ELLIPTA/ Preference Questionnaire version 1~* BREEZHALER followed by ELLIPTA/ Preference Questionnaire version 2

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BREEZHALER
Description: * ELLIPTA followed by BREEZHALER/ Preference Questionnaire version 1~* ELLIPTA followed by BREEZHALER/ Preference Questionnaire version 2~* BREEZHALER followed by ELLIPTA/ Preference Questionnaire version 1~* BREEZHALER followed by ELLIPTA/ Preference Questionnaire version 2

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BREEZHALER
Description: * ELLIPTA followed by BREEZHALER/ Preference Questionnaire version 1~* ELLIPTA followed by BREEZHALER/ Preference Questionnaire version 2~* BREEZHALER followed by ELLIPTA/ Preference Questionnaire version 1~* BREEZHALER followed by ELLIPTA/ Preference Questionnaire version 2
Study: NCT06737965

Intervention type: OTHER
Intervention: Outcomes mesurement
Description: * From the myocardial samples, 10 µm thick sections will be prepared and slides will be incubated with antibodies directed against proteins of interest (adrenergic receptors, protein kinase A, ryanodine receptor, PDE3, troponin). After washing, fluorescent secondary antibodies will be used and slides will be observed under a fluorescence microscope. Rest of the cardiac tissue will be frozen in liquid nitrogen in order to perform Western blots.~* Vessel samples will be put in a myograph to study contractile function. Concentration-response curves will be constructed by cumulative application of noradrenaline or U46619. For the study of endothelial function, arteries with and without functional endothelium will be pre-contracted to 80% of maximal contraction with U46619. When contraction reaches a plate, cumulative addition of different vasodilating agents will be performed. The vessels will also be cannulated on an arteriograph to assess dilation in response to flow and myogenic tone.
Study: NCT04703101

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-Modulated Radiation Therapy
Description: Undergo IMRT
Study: NCT04664491

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standardized COPD management
Description: In standardized management group, patients will receive a multifaceted and integrated disease management that follows recommendations in GOLD 2020 and China Guideline on COPD care. It contains the components below.~1. Maintenance therapy after initial treatment. In this study, patients' initial therapy is the prescribed inhalers at baseline. Maintenance therapy is the medications (LABA, LAMA, or ICS) prescribed for regular or long-term use after initial therapy.~2. Long-term follow-up and routine monitoring of symptoms measured by CAT, mMRC and SGRQ.~3. Regular pulmonary function testing for lung function monitoring~4. Strengthened COPD education~5. Behavioral modification, eg. encouragement of influenza/pneumococcal vaccination, providing smoking cessation counseling and pulmonary rehabilitation.

Intervention type: OTHER
Group type: OTHER
Intervention: Routine COPD management
Description: Patients will undergo usual care according to current clinical practice in study sites. Usual care is the routine care provided to patients. Prescription and dispense of medicine for COPD initial and maintenance therapy will be at the discretion of doctors.
Study: NCT04703101

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Given IV
Study: NCT06037655

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Total Neoadjuvant Treatment
Description: Adebrelimab (1200 mg) every three weeks intravenously; Mecapegfilgrastim (6 mg) every three weeks intravenously; Gemcitabine (1000 mg/m2) every three weeks on days 1 and 8 intravenously; Cisplatin (25 mg/m2) every three weeks on days 1 and 8 intravenously
Study: NCT06739265

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Golidocitinib plus CHOP
Description: Phase 1: dose escalation phase. Drug Golidocitinib: 2 dose level of 150 mg qod and 150 mg qd; CHOP regimen: cyclophosphamide (750 mg/m2 intravenously on day 1), epirubicin (70 mg/m2 intravenously on day 1), vindesine (4 mg intravenously on day 1), and prednisone (60 mg/m2 orally on days 1-5) in a 3-week cycle. Phase 2: dose expansion phase. Drug Golidocitinib: RP2D established in the phase I study; CHOP regimen: cyclophosphamide (750 mg/m2 intravenously on day 1), epirubicin (70 mg/m2 intravenously on day 1), vindesine (4 mg intravenously on day 1), and prednisone (60 mg/m2 orally on days 1-5) in a 3-week cycle.
Study: NCT04703101

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Surveillance
Description: Undergo NOM

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total Mesorectal Excision
Description: Undergo TME
Study: NCT04942457

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fasting
Description: Prolonged fasting for 7-10 days (caloric intake \<500 kcal in liquid form)
Study: NCT06530186

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LiviWell Postcoital Vaginal Insert
Description: subjects will use Livi within minutes of completion of sex, and will remove study device in under an hour.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LiviWell Postcoital Vaginal Insert
Description: subjects will use Livi within minutes of completion of sex, and will remove study device in under an hour.
Study: NCT05326724

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: The stainless steel needles are used to insert into the three points of Sishencong and the Baihui, and the Dazhui, once a week, once for 20 minutes, for 12 consecutive weeks.
Study: NCT05814354

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-A1811
Description: SHR-A1811 is a lyophilized powder for injection intravenously. Administered according to label, as one option for Physician's Choice.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine/Eribulin/Gemcitabine/Paclitaxel/Nab-paclitaxel
Description: Administered according to label, as one option for Physician's Choice (determined before randomization).
Study: NCT04991818

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: OneBiome microbiome profiling service
Description: participants will be asked to complete the user experience of the OneBiome service
Study: NCT06737848

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Single catheter adrenal vein sampling
Description: The clinical invasive procedure involves inserting a single catheter into the right and left adrenal veins to collect blood samples from both adrenal veins.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Double catheters adrenal vein sampling
Description: The clinical invasive procedure involves inserting double catheters into the right and left adrenal veins to collect blood samples from both adrenal veins.
Study: NCT06505967

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Qualia NAD+
Description: Qualia NAD+ is a novel dietary supplement, formulated to support the maintenance and enhancement of intracellular NAD levels.
Study: NCT05308108

Intervention type: PROCEDURE
Intervention: (Adeno)tonsillectomy
Description: registration of PORC in children with OSAS after (adeno)tonsillectomy
Study: NCT05361096

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational approach (Flipped learning)
Description: In the intervention group, the out-of-class stage started one week before the in-class stage of the relevant week. The researchers covered the topic of the week asynchronously in the virtual classroom in the learning management system. Students have been able to log into the system at anytime and anywhere and study the course video and other course materials repeatedly.~The in-class stage is the session in which the students in the intervention group come together with the researcher synchronously and conduct an online lesson. It was conducted one session per week for four weeks. The course was carried out synchronously on the Zoom platform during the in-class stage.
Study: NCT06399081

Intervention type: OTHER
Intervention: Observational
Description: Observational

Intervention type: OTHER
Intervention: Observational
Description: Observational
Study: NCT06505967

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Rice flour
Study: NCT06407518

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam oral solution
Description: Each individual administers the midazolam oral solution nightly from enrollment to the surgry.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Each individual administers placebo solution nightly from enrollment to the surgry.
Study: NCT06738732

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBD: GT4 Transdermal Delivery System
Description: CBD: GT4 Transdermal Delivery System
Study: NCT06737666

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tong-Xie-Yao-Fang
Description: Tong-Xie-Yao-Fang granules were taken 2 bags at a time, 2 times per day at 1h after meal for 4 weeks.
Study: NCT06128837

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan hydrochloride liposome Injection
Description: Irinotecan hydrochloride liposome Injection 80 mg/m² intravenously Days 1 q2wk

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topotecan
Description: Topotecan 1.2 mg/m² intravenously Days 1-5 q3w
Study: NCT06208358

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: tACS
Description: We aim to use tACS devices to improve the disrupted interpersonal interaction among gaming disorder individuals.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: tACS
Description: We aim to use tACS devices to improve the disrupted interpersonal interaction among gaming disorder individuals.
Study: NCT04859491

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Carbohydrate
Description: Participants have a one in three chance of consuming a carbohydrate beverage between two bouts of high-intensity exercise.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Carbohydrate-Protein
Description: Participants have a one in three chance of consuming a carbohydrate-protein beverage between two bouts of high-intensity exercise.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants have a one in three chance of consuming a placebo beverage between two bouts of high-intensity exercise.
Study: NCT05921188

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: VAULT Phase 4
Description: Children will receive an input-based word learning treatment that is designed based on principles of statistical learning.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VAULT Phase 4
Description: Children will receive an input-based word learning treatment that is designed based on principles of statistical learning.
Study: NCT06025383

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L-Citrulline
Description: 2 weeks of L-Citrulline supplementation (6 grams/day)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 weeks of microcrystalline cellulose supplementation (8 capsules/day)
Study: NCT06405204

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Myoinositol
Description: an enzymatic isoform of inositol and belongs to the vitamin B complex family

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Co-Enzyme Q10
Description: a lipid-soluble quinone, acting as an effective antioxidant,

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: an indoleamine with low molecular weight that is synthesized by different cells and organs in the body. More importantly, melatonin is an outstanding antioxidant

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Folic acid
Description: control
Study: NCT05545826

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vibrotactile coordinated reset
Description: The purpose of this study is to test the efficacy of vibrotactile coordinated reset stimulation on human subject participants with early stage Parkinson's disease
Study: NCT05616728

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EDP-235
Description: capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EDP-235
Description: capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: capsule
Study: NCT06562868

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bulk-fill Composite Resin
Description: The evaluation of the restorative material according to FDI criteria at baseline, 1 year and 2 years after application

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Posterior Composite Resin
Description: The evaluation of the restorative material according to FDI criteria at baseline, 1 year and 2 years after application

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High-filler Flowable Composite
Description: The evaluation of the restorative material according to FDI criteria at baseline, 1 year and 2 years after application
Study: NCT05432687

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: evaluation of deep abdominal wall before surgery
Description: : cough test (L guillarme) + ulstrasonography of transversus abdominis
Study: NCT05240417

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pontic-shield technique
Description: A 1mm thick fragment of the vestibular aspect of the root will remain after extraction (partial extraction)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Alveolar ridge preservation
Description: Particulate deproteinized bovine bone and porcine collagen membrane will be placed after tooth extraction
Study: NCT06511349

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YOLT-203
Description: The IP is administered intravenously at the predetermined dose.
Study: NCT05094128

Intervention type: DRUG
Intervention: Upadacitinib
Description: Tablet; Oral
Study: NCT05517304

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tcVNS
Description: active stimulation with transcutaneous Vagal Nerve Stimulation (tcVNS)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: sham
Description: sham stimulation
Study: NCT05984303

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human Umbilical Cord-derived Mesenchymal Stem Cells
Description: Human Umbilical Cord-derived Mesenchymal Stem Cells will be administered intravenously.
Study: NCT06195761

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: computer guided modified ridge splitting technique in horizontal bone deficiency in posterior mandible
Description: treatment plan includes harvesting and fixing the bone graft in posterior mandibular area using a computer-modified surgical guide

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: free hand modified ridge splitting technique in horizontal bone deficiency in posterior mandible
Description: treatment plan includes manually harvesting and fixing the bone graft in posterior mandibular area without a surgical guide.
Study: NCT04936464

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcutaneous tibial nerve stimulation (TTNS)
Description: TTNS is a non-invasive, surface electrode therapeutic stimulation technique available for home administration that has been proposed as a treatment for overactive bladder.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: transcutaneous electrical stimulation (TENS)
Description: The sham intervention is designed to appear almost identical to the TTNS intervention.
Study: NCT05597566

Intervention type: PROCEDURE
Intervention: modified electroconvulsive therapy
Description: The patient underwent MECT therapy. The treatment instrument is Xingmaitong IV ECT multifunctional treatment instrument (USA, SOMATICS THYMATRON company), fasting for 6 hours before surgery, emptying urine. Routine preoperative preparations were made, followed by intravenous injection of atropine, propofol, and succinylcholine chloride injection, artificial respiration, placement of dental pads, and electroconvulsive therapy. The whole process is completed by an anesthesiologist and a therapist in cooperation with each other. The first 3 times are once a day, and the next 5 times are once every other day. A total of 8 courses of treatment.
Study: NCT04936425

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OTSC Stentfix
Description: The OTSC stentfix will be placed during upper endoscopy after a self-expanding metal stent has been deployed.
Study: NCT04926155

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: The starting daily dose of metformin is 500mg once daily, and add a dose of 500mg per week until the target dose of 2000mg once daily if tolerated. Metformin will be continued until disease progression.
Study: NCT05242861

Intervention type: RADIATION
Intervention: Brachytherapy
Description: Applicator, dose, schedule, technology, image, 3D print, efficacy, toxicity of brachytherapy

Intervention type: RADIATION
Intervention: Brachytherapy
Description: Applicator, dose, schedule, technology, image, 3D print, efficacy, toxicity of brachytherapy

Intervention type: RADIATION
Intervention: Brachytherapy
Description: Applicator, dose, schedule, technology, image, 3D print, efficacy, toxicity of brachytherapy
Study: NCT05171738

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: skeletally anchored distal jet
Description: used from day one and activated every month

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: skeletally anchored distal jet
Description: used from day one and activated every month
Study: NCT06411184

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regulator T Cells
Description: Autologous Regulatory T-Lymphocytes 1\*10\^6/kg, 2\*10\^6/kg, 4\*10\^6/kg and 8\*10\^6/kg, respectively until restrictive toxic reaction occurs
Study: NCT01231191

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous acetaminophen
Description: Acetaminophen 1000 mg administered over 15 minutes intravenously as soon as feasible intraoperatively.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intravenous placebo
Description: Normal saline administered over 15 minutes intravenously as soon as feasible intraoperatively.
Study: NCT04910750

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pulse oximetry
Description: Pulse oximeters are a non-invasive, accurate and easy to use method of evaluating blood oxygen saturation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pulse oximetry
Description: Pulse oximeters are a non-invasive, accurate and easy to use method of evaluating blood oxygen saturation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Clinical Decision Support Algorithm
Description: Tablet-based clinical decision support algorithms, based on guidelines for the assessment and management of sick children under 5 years of age at primary care
Study: NCT05575518

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Optimised rifamycin
Description: optimised dose rifampicin with or without moxifloxacin
Study: NCT04322695

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rehabilitation Education Care Program
Description: The RECP contained the following domains: (1) assessment and detection of disability; (2) home exercise; (3) activities to improve mobility; (4) dietary management; (5) patient education; and (6) vocational counseling.
Study: NCT05242861

Intervention type: RADIATION
Intervention: Brachytherapy
Description: Applicator, dose, schedule, technology, image, 3D print, efficacy, toxicity of brachytherapy

Intervention type: RADIATION
Intervention: Brachytherapy
Description: Applicator, dose, schedule, technology, image, 3D print, efficacy, toxicity of brachytherapy
Study: NCT04392635

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TauTona Pneumoperitoneum Assist Device (TPAD)
Description: The TPAD is an experimental device used to assist with placement of Veress needle during laparoscopic surgery.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Standard of Care (SOC)
Description: Standard of Care was used for Veress needle insertion.